医保覆盖面的丧失 导致太平洋边缘的股价 暴跌超过60% Loss of Medicare coverage sends Pacific Edge's share prices plummeting over 60%.

新西兰癌症诊断公司Pacific Edge(Pacific Edge)的Pacific Edge在美医署提供商Novitas决定从2月23日起停止覆盖该公司的Cxbladder测试之后,股价下跌60%以上。 Pacific Edge, a New Zealand cancer diagnostics company, saw its share prices drop over 60% after the US Medicare provider, Novitas, decided to stop covering the company's Cxbladder tests starting February 23. Medicare保险的丧失占公司收入的一半以上,将在财政上对太平洋边缘产生重大影响。 The loss of Medicare coverage, which contributed over half of the company’s revenue, will significantly impact Pacific Edge financially. 该公司正在考虑采取法律行动和其他战略以恢复覆盖。 The company is considering legal action and other strategies to regain coverage.